Rigel Pharmaceuticals, Inc. (RIGL)
Largest Insider Buys in Sector
RIGL Stock Price History Chart
RIGL Stock Performance
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Insider Activity of Rigel Pharmaceuticals, Inc.
Over the last 12 months, insiders at Rigel Pharmaceuticals, Inc. have bought $0 and sold $90,916 worth of Rigel Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rigel Pharmaceuticals, Inc. have bought $688,400 and sold $76,674 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000,000 shares for transaction amount of $688,400 was made by RODRIGUEZ RAUL R (CEO, President) on 2022‑06‑09.
List of Insider Buy and Sell Transactions, Rigel Pharmaceuticals, Inc.
| 2024-02-05 | Sale | RODRIGUEZ RAUL R | CEO, President | 30,545 0.016% | $1.14 | $34,821 | -2.56% | |
| 2024-02-05 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 7,027 0.0037% | $1.14 | $8,011 | -2.56% | |
| 2024-02-05 | Sale | Santos David A | EVP, Chief Commercial Officer | 8,918 0.0047% | $1.14 | $10,167 | -2.56% | |
| 2024-02-02 | Sale | RODRIGUEZ RAUL R | CEO, President | 22,349 0.0116% | $1.13 | $25,261 | 0.00% | |
| 2024-02-02 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 5,601 0.0029% | $1.13 | $6,327 | 0.00% | |
| 2024-02-02 | Sale | Santos David A | EVP, Chief Commercial Officer | 5,601 0.0029% | $1.13 | $6,329 | 0.00% | |
| 2023-02-06 | Sale | RODRIGUEZ RAUL R | CEO, President | 20,340 0.012% | $1.75 | $35,595 | -26.75% | |
| 2023-02-02 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 5,389 0.0029% | $1.66 | $8,946 | -28.85% | |
| 2023-02-02 | Sale | Santos David A | EVP, Chief Commercial Officer | 5,388 0.0029% | $1.66 | $8,945 | -28.85% | |
| 2023-02-02 | Sale | Dummer Wolfgang | EVP & CMO | 5,389 0.0029% | $1.66 | $8,946 | -28.85% | |
| 2022-06-09 | RODRIGUEZ RAUL R | CEO, President | 1M 0.5572% | $0.69 | $688,400 | +76.39% | ||
| 2019-05-22 | Schorno Dean L | EVP &Chief Financial Officer | 50,000 0.0311% | $2.13 | $106,544 | +2.44% | ||
| 2018-10-12 | Sale | Cabatuan Nelson | Principal Accounting Officer | 10,000 0.006% | $3.12 | $31,200 | -26.61% | |
| 2018-09-17 | Sale | Duliege Anne-Marie | EVP & Chief Medical Officer | 37,500 0.0231% | $3.50 | $131,250 | -31.38% | |
| 2018-09-11 | Mayer Eldon C. III | EVP & Chief Commercial Officer | 50,000 0.0303% | $3.23 | $161,340 | -26.56% | ||
| 2018-09-10 | Mayer Eldon C. III | EVP & Chief Commercial Officer | 50,000 0.0301% | $3.28 | $164,210 | -28.05% | ||
| 2018-09-04 | Sale | Duliege Anne-Marie | EVP & Chief Medical Officer | 16,500 0.0101% | $3.51 | $57,861 | -31.20% | |
| 2018-08-23 | Mayer Eldon C. III | EVP & Chief Commercial Officer | 100,000 0.0606% | $2.82 | $282,320 | -14.64% | ||
| 2018-08-17 | RODRIGUEZ RAUL R | CEO, President | 114,000 0.0688% | $2.63 | $300,002 | -8.02% | ||
| 2018-07-02 | Sale | Duliege Anne-Marie | EVP & Chief Medical Officer | 5,000 0.0029% | $2.79 | $13,932 | -14.09% |
Insider Historical Profitability
| RODRIGUEZ RAUL R | CEO, President | 2036629 1.168% | $0.79 | 2 | 4 | +34.19% |
| Schorno Dean L | EVP & Chief Financial Officer | 402891 0.2311% | $0.79 | 1 | 3 | +2.44% |
| Santos David A | EVP, Chief Commercial Officer | 349093 0.2002% | $0.79 | 0 | 3 | |
| MPM BIOEQUITIES MASTER FUND LP | 10 percent owner | 4350516 2.495% | $0.79 | 0 | 1 | |
| Flynn James E | 10 percent owner | 3204167 1.8376% | $0.79 | 1 | 1 | <0.0001% |
| STEINMETZ MICHAEL | 10 percent owner | 1833597 1.0516% | $0.79 | 0 | 1 | |
| GALAKATOS NICHOLAS | 10 percent owner | 1833597 1.0516% | $0.79 | 0 | 1 | |
| EVNIN LUKE | 10 percent owner | 1687072 0.9675% | $0.79 | 0 | 26 | |
| MPM BIOVENTURES III QP LP | 10 percent owner | 1687072 0.9675% | $0.79 | 0 | 26 | |
| BVF PARTNERS L P/IL | 10 percent owner | 646559 0.3708% | $0.79 | 1 | 1 | <0.0001% |
| Mayer Eldon C. III | EVP & Chief Commercial Officer | 215000 0.1233% | $0.79 | 3 | 0 | <0.0001% |
| Dummer Wolfgang | EVP & CMO | 72459 0.0416% | $0.79 | 0 | 1 | |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | 53031 0.0304% | $0.79 | 0 | 6 | |
| DELEAGE JEAN | director | 11604 0.0067% | $0.79 | 0 | 26 | |
| Goodwin Bradford S | director | 10000 0.0057% | $0.79 | 1 | 0 | +109.25% |
| COOPER ROBIN D G | Sr. V.P. Pharmaceutical Scs. | 9000 0.0052% | $0.79 | 5 | 0 | +47.09% |
| ALTA PARTNERS II INC | 10 percent owner | 8050 0.0046% | $0.79 | 0 | 15 | |
| FRAZIER HEALTHCARE IV LP | 10 percent owner | 6180 0.0035% | $0.79 | 0 | 1 | |
| WELCH JAMES H | CFO, VP & Secretary | 3757 0.0022% | $0.79 | 0 | 1 | |
| Grossbard Elliott B | Sr. VP Medical Development | 2000 0.0011% | $0.79 | 1 | 0 | +4.66% |
| GADICKE ANSBERT | 10 percent owner | 1447 0.0008% | $0.79 | 0 | 1 | |
| VANCE DOLLY | EVP Corp. Affairs, G.C., Sect. | 575 0.0003% | $0.79 | 1 | 3 | |
| HENNER DENNIS | director | 0 0% | $0.79 | 0 | 27 | |
| FRAZIER ALAN D | director | 0 0% | $0.79 | 0 | 4 | |
| Maynard Ryan D | EVP & CFO | 0 0% | $0.79 | 0 | 5 | |
| Cabatuan Nelson | Principal Accounting Officer | 58 0% | $0.79 | 0 | 1 | |
| Duliege Anne-Marie | EVP & Chief Medical Officer | 0 0% | $0.79 | 0 | 6 | |
| SIMON NICHOLAS J III | director | 0 0% | $0.79 | 0 | 27 |
Institutional Investor Ownership
| Armistice Capital Llc | $22.73M | 8.76 | 15.36M | -10.18% | -$2.58M | 0.27 | |
| BlackRock | $21.9M | 8.44 | 14.8M | -2.63% | -$591,017.29 | <0.0001 | |
| Morgan Stanley | $21.37M | 8.23 | 14.44M | -0.1% | -$21,098.88 | <0.01 | |
| The Vanguard Group | $13.86M | 5.34 | 9.37M | +4.63% | +$613,026.34 | <0.0001 | |
| Soleus Capital Management, L.P. | $13.68M | 5.27 | 9.24M | -2.12% | -$296,877.63 | 0.13 | |
| Acadian Asset Management | $8.09M | 3.12 | 5.47M | +18.25% | +$1.25M | 0.03 | |
| Geode Capital Management | $5.61M | 2.16 | 3.79M | +2.7% | +$147,721.49 | <0.01 | |
| State Street | $5.53M | 2.13 | 3.73M | +4.32% | +$228,988.58 | <0.0001 | |
| Nuveen | $4.77M | 1.84 | 3.22M | +30.68% | +$1.12M | <0.01 | |
| Jacobs Levy Equity Management | $3.39M | 1.31 | 2.29M | -14.7% | -$584,061.32 | 0.02 | |
| Renaissance Technologies | $2.99M | 1.15 | 2.02M | +53.25% | +$1.04M | 0.01 | |
| Cm Management Llc | $2.96M | 1.14 | 2M | +17.65% | +$444,000.00 | 0.14 | |
| Assenagon Asset Management S.A. | $2.95M | 1.14 | 1.99M | 0% | +$0 | 0.01 | |
| Millennium Management LLC | $2.77M | 1.07 | 1.87M | +141.41% | +$1.62M | <0.01 | |
| Voya Investment Management LLC | $2.68M | 1.03 | 1.81M | -13.34% | -$413,157.23 | <0.01 | |
| Macquarie Group | $2.37M | 0.91 | 1.6M | 0% | +$0 | <0.01 | |
| Northern Trust | $2.14M | 0.83 | 1.45M | -6.09% | -$138,906.88 | <0.0001 | |
| Gsa Capital Partners Llp | $2.04M | 0.79 | 1.38M | -3.33% | -$70,327.94 | 0.16 | |
| Healthcare Of Ontario Pension Plan Trust Fund | $2.01M | 0.78 | 1.36M | New | +$2.01M | 0.01 | |
| Stonepine Capital Management Llc | $1.54M | 0.59 | 1.04M | New | +$1.54M | 1.24 | |
| Wellington Management Company | $1.23M | 0.48 | 834,158 | New | +$1.23M | <0.0001 | |
| Charles Schwab | $1.1M | 0.42 | 743,615 | 0% | +$0 | <0.0001 | |
| Connor Clark & Lunn Investment Management Ltd | $1.08M | 0.42 | 732,563 | +24.37% | +$212,464.31 | <0.01 | |
| Ubs Oconnor Llc | $995,670.00 | 0.38 | 672,750 | -25.2% | -$335,345.80 | 0.09 | |
| Two Sigma Advisers LP | $922,323.00 | 0.36 | 623,191 | -5.38% | -$52,405.34 | <0.01 | |
| Los Angeles Capital Management LLC | $892,622.00 | 0.34 | 603,123 | +49.14% | +$294,093.75 | <0.01 | |
| Squarepoint Ops LLC | $885,520.00 | 0.34 | 598,324 | +84.79% | +$406,309.06 | <0.01 | |
| Bridgeway Capital Management | $881,192.00 | 0.34 | 595,400 | -11.19% | -$111,000.00 | 0.02 | |
| BNY Mellon | $775,544.00 | 0.3 | 524,016 | -7.41% | -$62,060.87 | <0.0001 | |
| Marshall Wace | $649,071.00 | 0.25 | 438,562 | New | +$649,071.00 | <0.01 | |
| Citadel Advisors LLC | $641,929.00 | 0.25 | 433,736 | +1,637.38% | +$604,980.82 | <0.0001 | |
| Zacks Investment Management | $627,929.00 | 0.24 | 424,276 | +40.33% | +$180,449.15 | 0.01 | |
| Goldman Sachs | $606,033.00 | 0.23 | 409,482 | -19.98% | -$151,337.31 | <0.0001 | |
| AllianceBernstein | $465,800.00 | 0.18 | 314,730 | 0% | +$0 | <0.0001 | |
| Xtx Topco Ltd | $465,556.00 | 0.18 | 314,565 | +464.96% | +$383,151.11 | 0.03 | |
| RhumbLine Advisers | $352,143.00 | 0.14 | 237,943 | +3.52% | +$11,974.25 | <0.0001 | |
| Fidelity Investments | $305,794.00 | 0.12 | 206,618 | +0.9% | +$2,737.99 | <0.0001 | |
| Nj State Employees Deferred Compensation Plan | $296,000.00 | 0.11 | 200,000 | 0% | +$0 | 0.04 | |
| UBS | $265,163.00 | 0.1 | 179,164 | +18.37% | +$41,145.52 | <0.0001 | |
| Ohio Strs | $261,000.00 | 0.1 | 177,000 | 0% | +$0 | <0.01 | |
| Two Sigma | $226,486.00 | 0.09 | 153,031 | +48.33% | +$73,797.28 | <0.0001 | |
| Barclays | $223,000.00 | 0.09 | 150,568 | -38.92% | -$142,085.34 | <0.0001 | |
| Susquehanna International Group | $198,249.00 | 0.08 | 133,952 | -55.34% | -$245,688.93 | <0.0001 | |
| Man Group Plc | $179,083.00 | 0.07 | 121,002 | New | +$179,083.00 | <0.0001 | |
| Russell Investments Group Ltd | $173,838.00 | 0.07 | 117,459 | -19.3% | -$41,587.68 | <0.0001 | |
| Connecticut Wealth Management, LLC | $170,496.00 | 0.07 | 115,200 | 0% | +$0 | 0.01 | |
| Bank of America | $165,815.00 | 0.06 | 112,037 | -34.27% | -$86,458.76 | <0.0001 | |
| T. Rowe Price | $168,000.00 | 0.06 | 113,047 | +8.77% | +$13,550.33 | <0.0001 | |
| JPMorgan Chase | $152,015.00 | 0.06 | 102,713 | -19.89% | -$37,748.82 | <0.0001 | |
| Qube Research & Technologies | $134,248.00 | 0.05 | 90,708 | New | +$134,248.00 | <0.0001 |